 Citi Research has raised the price target on Amylyx Pharmaceuticals Incs NASDAQ: AMLX to 33 from 32, with a Buy rating. It says the small market opportunity for the newly approved amyotrophic lateral sclerosis ALS drug in Canada 100 million peak. 